Consistently, Eμ‐MYC‐driven B‐cell lymphomagenesis in mice depends on CHK1 [19] and tumors from these mice are highly responsive to CHK1 inhibitors [20], as are several human blood cancer cell lines, including those from Burkitt and Diffuse Large B‐cell Lymphomas (DLBCL) [19, 21]. Here, CHEK1 is linked to hematopoietic and lymphoid system neoplasm.